Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.

Miguel Sanmamed, MD, PhD

Assistant Professor Adjunct

About

Titles

Assistant Professor Adjunct

Departments & Organizations

Internal Medicine

Education & Training

PhD: Oviedo University (2011)

MD: Santiago de Compostel University (2005)

Research

Research at a Glance

Yale Co-Authors

Frequent collaborators of Miguel Sanmamed's published research.

Kurt Schalper, MD, PhD
View Full Profile
View 3 Common Publications
Lieping Chen, MD, PhD
View Full Profile
View 3 Common Publications
David Rimm, MD, PhD
View Full Profile
View 2 Common Publications
María Villalba Esparza
View Full Profile
View 2 Common Publications
Amer Zeidan, MBBS, MD
View Full Profile
View Common Publication
Angelo Porciuncula
View Full Profile
View Common Publication

Publications

2026

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Rohrberg K, Melero I, Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim H, Lee D, Italiano A, Cassier P, Hiret S, Deva S, Kim T, Blumenschein G, Eefsen R, Henick B, Perro M, Umaña P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mücke M, Heichinger C, Tran V, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Deak L, Markert C, Moreno V. First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. Journal For ImmunoTherapy Of Cancer 2026, 14: e012729. PMID: 42320980, PMCID: PMC13289304, DOI: 10.1136/jitc-2025-012729.
Peer-Reviewed Original Research
MeSH Keywords
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Lopez-Janeiro A, González-Gomariz J, Issa F, Hester J, Porciuncula A, Teijeira A, Luri-Rey C, Ruiz-Guillamon D, Perez-Gracia J, Perez-Ruiz E, Barragan I, Martín-Algarra S, Sanmamed M, Ortego I, Rodriguez-Ruiz M, Alexandru R, Rodriguez I, Arrieta-Aranzueque S, Rimm D, Aung T, Schalper K, de Andrea C, Melero I. Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. Journal Of Clinical Investigation 2026, 136: e200987. PMID: 42065248, PMCID: PMC13132367, DOI: 10.1172/jci200987.
Peer-Reviewed Original Research
MeSH Keywords
Fulzerasib plus cetuximab in first-line KRASG12C -mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
Gregorc V, Majem M, Lo Russo G, Maio M, Salvagni S, Gutiérrez-Calderon V, Gonzalez-Cao M, Sandiego Contreras S, Koumarianou A, Bearz A, Bernabé-Caro R, Viteri S, de Sanmamed M, Zagouri F, Morán Bueno T, Lazzari C, Martínez-Recio S, Giménez-Capitán A, Zhang Y, Shan Y, Zhu H, Zhao C, Shen H, Wang Y, Rosell R. Fulzerasib plus cetuximab in first-line KRASG12C -mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. The Lancet Oncology 2026, 27: 432-441. PMID: 41926959, DOI: 10.1016/s1470-2045(25)00764-8.
Peer-Reviewed Original Research
MeSH Keywords
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
Marco S, Fernández M, Honorato B, Juanarena N, Sainz C, Andueza A, Gould D, Anderson S, de Andrea C, Domínguez P, Wong P, Vásquez C, Narinda I, Unzu C, Isola S, Tavira B, Ariz M, Camps G, Sanmamed M, Pardo J, Labiano S, Alonso M, Marco-Sanz J, Guruceaga E, Collantes M, Simón J, Peñuelas I, Fernández-Irigoyen J, Santamaría E, Prieto J, Dubrot J. Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer Cell 2026, 44: 995-1011.e12. PMID: 41875889, DOI: 10.1016/j.ccell.2026.02.013.
Peer-Reviewed Original Research
An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Endocrine Abstracts 2026 DOI: 10.1530/endoabs.116.c1.
Peer-Reviewed Original Research
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond. Journal Of Clinical Oncology 2026, 44: 1062-1064. PMID: 41570262, DOI: 10.1200/jco-25-02654.
Commentaries, Editorials and Letters
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
Sanmamed M, de Andrea C, Ruiz-Guillamón D, Rodriguez-Ruiz M, Ortego I, Eguren-Santamaría I, Benito A, López-Janeiro A, Gonzalez Gomariz J, Villalba-Esparza M, Molina A, Krasko A, Ponz-Sarvise M, Lopez-Picazo J, Gomis G, Molero-Glez P, Alexandru R, Pérez-Domínguez P, Rodriguez I, Sánchez-Gregorio S, Perez-Gracia J, Melero I. Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab. Clinical Cancer Research 2026, 32: 1036-1045. PMID: 41543348, DOI: 10.1158/1078-0432.ccr-25-2502.
Peer-Reviewed Original Research
Orthotopic pleural mesothelioma mouse model
García R, Moreno D, Camps G, Vera L, Sanmamed M, Berraondo P, Aranda F. Orthotopic pleural mesothelioma mouse model. Methods In Cell Biology 2026 DOI: 10.1016/bs.mcb.2026.06.002.
Books